Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phosphare-IDA-04: Iron Isomaltoside vs Ferric Carboxymaltose in IDA
NCT03238911Phase 3Completed
- Sponsor
- Pharmacosmos
- Start
- Oct 2017
- Primary completion
- Jun 2018
- Modality
- Inorganic Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of ferric derisomaltose in iron deficiency anemia (IDA) (2 arms), sponsored by Pharmacosmos. Primary endpoint: Incidence of Hypophosphatemia (S-phosphate Level <2 mg/dL). Started Oct 2017; status: completed.
02
Drugs
ferric derisomaltose
03
Conditions
iron deficiency anemia (IDA)
Beyond the preview
Go deeper on NCT03238911.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03238911.